The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
Researchers focused on using existing computational methods to fill in gaps in the human microbiome without reference genomes.
Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
The Swiss firm's ScaiVision software identifies disease-linked cells using AI, data visualization, and automation of hypothesis testing.
The study identified one genetic and three protein-based biomarkers associated with outcome in Pseudomonas bloodstream infections.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The German firm grew revenues to €5.3 million for the first nine months of the year from €976,000 a year ago, but its net loss expanded 48 percent year over year.
Johns Hopkins researchers added protein analysis to circulating tumor DNA testing to better detect early-stage pancreatic cancer.
The partners aim to enable the early prediction of clinical efficacy of Alligator's pipeline candidates by analyzing potential systemic biomarkers.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.